{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,31]],"date-time":"2023-12-31T23:11:29Z","timestamp":1704064289277},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s11899-021-00616-6","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T13:02:55Z","timestamp":1615467775000},"page":"40-44","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Lessons Learned Treating Patients with Multiple Myeloma in Resource-Constrained Settings"],"prefix":"10.1007","volume":"16","author":[{"given":"Guillermo J.","family":"Ruiz-Arg\u00fcelles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"G\u00f3mez-Almaguer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,11]]},"reference":[{"key":"616_CR1","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/ejh.12790","volume":"97","author":"C Ramsenthaler","year":"2016","unstructured":"Ramsenthaler C, Kane P, Gao W, Siegert RJ, Edmonds PM, Schey SA, et al. Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis. Eur J Haematol. 2016;97:416\u201329.","journal-title":"Eur J Haematol"},{"key":"616_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.4314\/gmj.v53i1.8","volume":"53","author":"ME Acquah","year":"2019","unstructured":"Acquah ME, Hsing AW, McGuire V, Wang S, Birmann B, Dei-Adomakoh Y. Presentation and survival of multiple myeloma patients in Ghana: a review of 169 cases. Ghana Med J. 2019;53:52\u20138.","journal-title":"Ghana Med J"},{"key":"616_CR3","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/bcj.2017.14","volume":"7","author":"N Lee","year":"2017","unstructured":"Lee N, Moon S, Lee J, Park H, et al. Discrepancies between the percentage of plasma cells in bone marrow aspiration and BM biopsy: impact on the revised IMWG diagnostic criteria of multiple. Blood Cancer J. 2017;7:530.","journal-title":"Blood Cancer J"},{"key":"616_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","volume":"91","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2016;91:101\u201319.","journal-title":"Mayo Clin Proc"},{"key":"616_CR5","doi-asserted-by":"crossref","unstructured":"Diamond BT, Rustad E, Maclachlan K, Thoren K, Ho C, Roshal M, et al. Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity. Blood Rev. 2020;100732.","DOI":"10.1016\/j.blre.2020.100732"},{"key":"616_CR6","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.3892\/ol.2017.5723","volume":"13","author":"L Lambert","year":"2017","unstructured":"Lambert L, Ourednicek P, Meckova Z, Gavelli G, Strau J. Whole-body low-dose computed tomography in multiple myeloma staging: superior diagnostic performance in the detection of bone lesions, vertebral compression. Oncol Lett. 2017;13:2490\u20134.","journal-title":"Oncol Lett"},{"key":"616_CR7","first-page":"421","volume":"8","author":"B Jamet","year":"2019","unstructured":"Jamet B, Bailly C, Carlier T, Michaud A-V, Touzeau C, Moreau P, et al. FDG PET in multiple myeloma. In: Molecular imaging in multiple myeloma. Am J Nucl Med Mol Imaging. 2019;8:421\u20137.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"616_CR8","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, Miguel JS, Durie BGM, Crowley JJ, Barlogie B, Blad\u00e9 J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412\u201320.","journal-title":"J Clin Oncol"},{"issue":"91","key":"616_CR9","doi-asserted-by":"publisher","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","volume":"26","author":"RJ D\u2019Amato","year":"1994","unstructured":"D\u2019Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;26(91):4082\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"616_CR10","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"18","author":"S Singhal","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;18:1565\u201371.","journal-title":"N Engl J Med"},{"key":"616_CR11","doi-asserted-by":"publisher","first-page":"4444","DOI":"10.1200\/JCO.2003.07.200","volume":"21","author":"MA Dimopoulos","year":"2003","unstructured":"Dimopoulos MA, Anagnostopoulos A, Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol. 2003;21:4444\u201354.","journal-title":"J Clin Oncol"},{"key":"616_CR12","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"16","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;16:2487\u201398.","journal-title":"N Engl J Med"},{"key":"616_CR13","first-page":"3071","volume":"61","author":"T Hideshima","year":"2001","unstructured":"Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071\u20136.","journal-title":"Cancer Res"},{"key":"616_CR14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/10245330701214236","volume":"12","author":"M Wang","year":"2007","unstructured":"Wang M, Giralt S, Delasalle K, Handy B, Alexanian R. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology. 2007;12:235\u20139.","journal-title":"Hematology"},{"key":"616_CR15","first-page":"1","volume":"11","author":"I Murrieta-\u00c1lvarez","year":"2020","unstructured":"\u2022 Murrieta-\u00c1lvarez I, Steensma DP, Olivares-Gazca JC, Olivares-Gazca M, Le\u00f3n-Pe\u00f1a A, Cantero-Fortiz Y, et al. Treatment of persons with multiple myeloma in underprivileged circumstances: real-world data from a single institution. Acta Haematol. 2020;11:1\u20137 Single center long term analysis of the treatment of patients with myeloma employing a simplified and affordable approach.","journal-title":"Acta Haematol"},{"key":"616_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/CMAR.S105163","volume":"9","author":"M Mohan","year":"2012","unstructured":"Mohan M, Matin A, Davies FE. Update on the optimal use of bortezomib in the treatment of multiple myeloma. Cancer Manag Res. 2012;9:51\u201363.","journal-title":"Cancer Manag Res"},{"key":"616_CR17","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2141.2008.07359.x","volume":"143","author":"S Jagannath","year":"2008","unstructured":"Jagannath S, Barlogie B, Berenson JR, Siegel DS, Irwin D, Richardson PG, et al. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol. 2008;143:537\u201340.","journal-title":"Br J Haematol"},{"key":"616_CR18","first-page":"530","volume":"7","author":"C Niu","year":"2017","unstructured":"Niu C, Jin H, Li M, Zhu S, Zhou L, Jin F, et al. Low-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and \u03b3\u03b4 T cell-mediated lysis in multiple myeloma. Oncotarget. 2017;7:530.","journal-title":"Oncotarget"},{"key":"616_CR19","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1200\/JCO.2015.66.0662","volume":"34","author":"SM Lee","year":"2016","unstructured":"Lee SM, Backenroth D, Cheung YKK, Hershman DL, Vulih D, Anderson B, et al. Case example of dose optimization using data from bortezomib dose-finding clinical trials. J Clin Oncol. 2016;34:1395\u2013401.","journal-title":"J Clin Oncol"},{"key":"616_CR20","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1177\/1078155210386268","volume":"17","author":"JP Vanderloo","year":"2011","unstructured":"Vanderloo JP, Pomplun ML, Kolesar JM. Stability of unused reconstituted bortezomib in original manufacturer vials. J Oncol Pharm. 2011;17:400\u20132.","journal-title":"J Oncol Pharm"},{"key":"616_CR21","doi-asserted-by":"publisher","unstructured":"Vela-Ojeda J, G\u00f3mez-Almaguer D, Espinoza-Zamora R, Ram\u00edrez-Alvarado AG, Villalobos A, Herrera-Rojas MA et al. Prescription patterns of daratumumab in patients with MM in underprivileged circumstances: a multicenter experience in Mexico Arch Med Res 2021. https:\/\/doi.org\/10.1016\/j.arcmed.2021.02.008.","DOI":"10.1016\/j.arcmed.2021.02.008"},{"key":"616_CR22","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/bmt.2009.71","volume":"44","author":"A L\u00f3pez-Otero","year":"2009","unstructured":"\u2022 L\u00f3pez-Otero A, Ruiz-Delgado G, Rujiz-Arg\u00fcelles A. A simplified method for stem cell autografting in multiple myeloma: a single institution experience. Bone Marrow Transplant. 2009;44:715\u20139 Description of the method and results of a simplified approach to autograft myeloma patients on an outpatient basis.","journal-title":"Bone Marrow Transplant"},{"key":"616_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1179\/102453310X12583347009892","volume":"15","author":"GJ Ruiz-Arg\u00fcelles","year":"2010","unstructured":"Ruiz-Arg\u00fcelles GJ. Whither the bone marrow transplant? Hematology. 2010;15:1\u20133.","journal-title":"Hematology"},{"key":"616_CR24","doi-asserted-by":"crossref","unstructured":"Vela-Ojeda J, Garc\u00eda-Ruiz-Esparza MA, Padilla-Gonz\u00e1lez Y, G\u00f3mezAlmaguer D, Guti\u00e9rrez-Aguirre CH, G\u00f3mez-Rangel D, et al. Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus I.V. melphalan. Ann Hematol. 2007;86:277\u201382.","DOI":"10.1007\/s00277-006-0235-9"},{"issue":"4","key":"616_CR25","first-page":"181","volume":"68","author":"M Le\u00f3n-Gonz\u00e1lez","year":"2016","unstructured":"Le\u00f3n-Gonz\u00e1lez M, Le\u00f3n-Pe\u00f1a AA, Vallejo-VIllalobos MF, N\u00fa\u00f1ez-Cort\u00e9s AK, Ruiz-Arg\u00fcelles A, Ruiz-Arg\u00fcelles GJ. Mexican biosimilar filgrastim for autologous hematopoietic stem cell mobilization and transplantation. Rev Investig Clin. 2016;68(4):181\u20133.","journal-title":"Rev Investig Clin"},{"issue":"5","key":"616_CR26","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/jca.21707","volume":"34","author":"A G\u00f3mez-De Le\u00f3n","year":"2019","unstructured":"G\u00f3mez-De Le\u00f3n A, Bugarin-Estrada E, Colunga-Pedraza PR, et al. Efficacy of three filgrastim-intended copies for hematopoietic stem cell mobilization in healthy adult and pediatric donors in M\u00e9xico. J Clin Apher. 2019;34(5):537\u201344.","journal-title":"J Clin Apher"},{"issue":"12","key":"616_CR27","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1111\/trf.15547","volume":"59","author":"CH Guti\u00e9rrez-Aguirre","year":"2019","unstructured":"Guti\u00e9rrez-Aguirre CH, Alvarado-Navarro DM, Palomares-Leal A, Mej\u00eda-Jaramillo G, Salazar-Riojas R, Le\u00f3n AGD, et al. Reduced-dose plerixafor as a mobilization strategy in autologous hematopoietic cell transplantation: a proof of concept study. Transfusion. 2019;59(12):3721\u20136.","journal-title":"Transfusion"},{"key":"616_CR28","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S2352-3026(20)30184-8","volume":"7","author":"GJ Ruiz-Arg\u00fcelles","year":"2020","unstructured":"\u2022 Ruiz-Arg\u00fcelles GJ. Lessons learned starting a bone marrow transplantation programme in a resource-constrained setting. Lancet Haematol. 2020;7:509\u201310 A summary of over 25 years of experience conducting both allo and autografts in underprivileged circumstances.","journal-title":"Lancet Haematol"},{"issue":"29","key":"616_CR29","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"PL McCarthy","year":"2017","unstructured":"McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35(29):3279\u201389.","journal-title":"J Clin Oncol"},{"key":"616_CR30","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1002\/cncr.31305","volume":"124","author":"L Tar\u00edn-Arzaga","year":"2018","unstructured":"Tar\u00edn-Arzaga L, Arredondo-Campos D, Mart\u00ednez-Pacheco V, Mart\u00ednezGonz\u00e1lez O, Ram\u00edrez-L\u00f3pez A, G\u00f3mez-De Le\u00f3n A, et al. Impact of the affordability of novel agents in patients with multiple myeloma: real-world data of current clinical practice in M\u00e9xico. Cancer. 2018;124:1946\u201353.","journal-title":"Cancer"},{"key":"616_CR31","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1080\/10428194.2020.1804558","volume":"61","author":"C Pe\u00f1a","year":"2020","unstructured":"Pe\u00f1a C, Riva E, Schutz N, Tar\u00edn-Arzaga L, Mart\u00ednez-Cordero H, Bove V, et al. Different outcomes for transplant eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: A GELAMM study. Leukemia Lymph. 2020;61:3112\u20139.","journal-title":"Leukemia Lymph"},{"key":"616_CR32","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","volume":"366","author":"A Palumbo","year":"2012","unstructured":"Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366:1759\u201369.","journal-title":"N Engl J Med"},{"issue":"1","key":"616_CR33","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000493569","volume":"141","author":"GJ Ruiz-Arg\u00fcelles","year":"2019","unstructured":"Ruiz-Arg\u00fcelles GJ. Factors involved in the selection of treatment in patients with hematological malignancies. Acta Haematol. 2019;141(1):54.","journal-title":"Acta Haematol"},{"key":"616_CR34","doi-asserted-by":"publisher","first-page":"64","DOI":"10.4067\/s0034-98872018000100064","volume":"146","author":"C Pe\u00f1a","year":"2018","unstructured":"Pe\u00f1a C, Ortiz M, Voisin J, Peralta A, Balboa V, Delgado F. Sensibilidad diagn\u00f3stica de electroforesis de prote\u00ednas y cadenas livianas libres s\u00e9ricas en gammapat\u00edas monoclonales. Rev Med Chil. 2018;146:64\u20137.","journal-title":"Rev Med Chil"},{"issue":"1","key":"616_CR35","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/hon.2552","volume":"37","author":"L Sekine","year":"2019","unstructured":"Sekine L, Ziegelmann PK, Manica D, Fonte Pithan C, Sosnoski M, Morais VD, et al. Frontline treatment for transplant-eligible multiple myeloma: a 6474 patients network metaanalysis. Hematol Oncol. 2019;37(1):62\u201374.","journal-title":"Hematol Oncol"},{"issue":"Suppl 1","key":"616_CR36","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1016\/S0049-3848(16)30103-7","volume":"140","author":"FW Leebeek","year":"2016","unstructured":"Leebeek FW. Update of thrombosis in multiple myeloma. Thromb Res. 2016;140(Suppl 1):S76\u201380.","journal-title":"Thromb Res"},{"key":"616_CR37","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3816\/CLM.2009.n.036","volume":"9","author":"L Pour","year":"2009","unstructured":"Pour L, Adam Z, Buresova L, Krejci M, Krivanova A, Sandecka V, et al. Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma. 2009;9:151\u20133.","journal-title":"Clin Lymphoma Myeloma"},{"key":"616_CR38","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fonc.2015.00040","volume":"5","author":"G Talamo","year":"2015","unstructured":"Talamo G, Dimaio C, Abbi KK, et al. Current role of radiation therapy for multiple myeloma. Front Oncol. 2015;5:40.","journal-title":"Front Oncol"},{"key":"616_CR39","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jama.2016.19425","volume":"317","author":"AL Himelstein","year":"2017","unstructured":"Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, et al. Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA - J Am Med Assoc. 2017;317:48\u201358.","journal-title":"JAMA - J Am Med Assoc"},{"issue":"10","key":"616_CR40","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S1470-2045(10)70198-4","volume":"11","author":"P Gimsing","year":"2010","unstructured":"Gimsing P, Carlson K, Turesson I, Fayers P, Waage A, Vangsted A, et al. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. Lancet Oncol. 2010 Oct;11(10):973\u201382.","journal-title":"Lancet Oncol"},{"key":"616_CR41","first-page":"470","volume":"113","author":"C Gerecke","year":"2016","unstructured":"Gerecke C, Fuhrmann S, Strifler S, Schmidt-Hieber M, Einsele H, Knop S. Diagnostik und therapie des multiplen myeloms. Dtsch Arztebl Int. 2016;113:470\u20136.","journal-title":"Dtsch Arztebl Int"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-021-00616-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-021-00616-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-021-00616-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T23:28:57Z","timestamp":1698017337000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-021-00616-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["616"],"URL":"https:\/\/doi.org\/10.1007\/s11899-021-00616-6","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"5 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}